[go: up one dir, main page]

WO2001042463A1 - Amelioration de la stabilite de la proteine flint (fas ligand inhibitory protein) par glycosylation a liaison o - Google Patents

Amelioration de la stabilite de la proteine flint (fas ligand inhibitory protein) par glycosylation a liaison o Download PDF

Info

Publication number
WO2001042463A1
WO2001042463A1 PCT/US2000/030166 US0030166W WO0142463A1 WO 2001042463 A1 WO2001042463 A1 WO 2001042463A1 US 0030166 W US0030166 W US 0030166W WO 0142463 A1 WO0142463 A1 WO 0142463A1
Authority
WO
WIPO (PCT)
Prior art keywords
flint
linked
seq
replacing
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/030166
Other languages
English (en)
Inventor
Jirong Lu
Derrick Ryan Witcher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to EP00982080A priority Critical patent/EP1244783A1/fr
Priority to AU19152/01A priority patent/AU1915201A/en
Publication of WO2001042463A1 publication Critical patent/WO2001042463A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • TNFR proteins tumor necrosis factor receptor proteins
  • FLINT Fas Ligand Inhibitory Protein
  • Fas-FasL signal transduction pathway Increased activation of the Fas-FasL signal transduction pathway is implicated in a number of pathological conditions, including runaway apoptosis (Kondo et al . , Nature Medicine 3(4):409-413 (1997); Galle et al . , J. Exp . Med . 182:1223-1230 (1995)), and inflammatory disease resulting from neutrophil activation (Miwa et al . , . Nature Medicine 4:1287 (1998)).
  • Rapid apoptosis is a level of apoptosis greater than normal, including apoptosis occurring at an inappropriate time.
  • Pathological conditions caused by runaway apoptosis include, for example, organ failure in the liver, kidneys and pancreas.
  • Inflammatory diseases associated with excessive neutrophil activation include sepsis, ARDS, SIRS and MODS.
  • Compounds such as FLINT and analogs thereof, which inhibit the binding of Fas to FasL, and LIGHT to LT ⁇ R and/or TR2/HVEM receptors, can be used to treat or prevent diseases or conditions that may be associated with apoptosis and/or inflammation.
  • the therapeutic utility of FLINT could be enhanced by modifications that improve pharmacological properties (e.g., enhanced potency, stability, longer in vivo half-lives, and/or greater affinity for FasL) , pharmaceutical properties (e.g., decreased aggregation and surface adsorption, increased solubility and ease of formulation) and/or chemical properties such as susceptibility to proteolysis.
  • pharmacological properties e.g., enhanced potency, stability, longer in vivo half-lives, and/or greater affinity for FasL
  • pharmaceutical properties e.g., decreased aggregation and surface adsorption, increased solubility and ease of formulation
  • chemical properties such as susceptibility to proteolysis.
  • glycosylation can modulate structure and stability of a protein, influence the activity of signaling molecules, impact molecular recognition, and affect the activity of enzymes (See e.g. P. Van den Steen et al . Critical Reviews in Biochemistry and Molecular Biology, 33(3), 151-208; P.
  • FLINT is known to be potentially glycosylated (See e.g. WO 99/50413, WO 99/14330), there is no current understanding as to specific glycosylation patterns nor the impact of specific glycosylation patterns, on the stability of the molecule, or analogs thereof.
  • the therapeutic utility of FLINT is likely to be impacted by the glycosylation pattern.
  • the potency and/or stability of the molecule could be directly impacted by glycosylation, as is known for other proteins.
  • the invention disclosed herein relates to a solution to this problem. Specifically, shown herein is that FLINT and analogs produced in mammalian cells have multiple glycosylation species, and that species having O-linked glycosylation are more stable to degradation.
  • the present invention addresses the need for a FLINT molecule, including analogs thereof, with enhanced stability.
  • the invention relates to O-linked glycosylated FLINT polypeptides, N-linked glycosylated FLINT polypeptides, and N/O- linked FLINT polypeptides, and methods for producing and using same.
  • the compositions of the present invention relate further to O-linked glycosylated analogs of FLINT, N/0-linked species, and N-linked glycosylated species of FLINT analogs, wherein one or more complex carbohydrate structures are linked to a threonine, serine, or asparagine residue.
  • the FLINT polypeptides of the invention provide enhanced physical, thermal, and conformational stability to FLINT molecules.
  • an oligosaccharide is O-linked to T216 of SEQ ID NO : 1 (coincident site T245 of SEQ ID NO : 3 ) and/or T174 of SEQ ID NO : 1 (coincident site T203 of SEQ ID NO: 3) .
  • the invention relates to FLINT polypeptides comprising O-linked oligosaccharides.
  • the invention relates to FLINT polypeptides comprising O-linked oligosaccharides complexed with a divalent metal cation.
  • the present invention relates to FLINT polypeptides comprising O-linked oligosaccharides wherein said oligosaccharides are covalently attached at T216 of SEQ ID NO : 1 (T245 of SEQ ID NO : 3 ) and/or T174 of SEQ ID NO:l.
  • the present invention relates to a FLINT analog comprising N-linked oligosaccharides.
  • the invention relates to a FLINT analog polypeptide comprising O-linked and N-linked oligosaccharides wherein said O-linked oligosaccharides are located at T216 of SEQ ID NO : 1 (T245 of SEQ ID NO : 3 ) and said N-linked oligosaccharides are located at N144 of SEQ ID NO : 1.
  • the invention relates to a method for producing a FLINT analog polypeptide comprising O-linked oligosaccharides at T216 of SEQ ID NO : 1 said method comprising expression of a vector encoding a protease resistant FLINT analog in a suitable mammalian cell line, for example, AVI2, 293 EBNA, or CHO.
  • a suitable mammalian cell line for example, AVI2, 293 EBNA, or CHO.
  • the invention relates to a composition substantially enriched in a FLINT analog polypeptide having O-linked oligosaccharide covalently linked to T216 of SEQ ID NO : 1.
  • the invention relates to therapeutic and clinical uses of a FLINT analog polypeptide substantially comprising O-linked oligosaccharides at T216 to prevent or treat a disease or condition in a mammal in need of such prevention or treatment.
  • the invention relates to therapeutic and clinical uses of a FLINT analog polypeptide of the present invention to prevent or treat diseases including acute lung injury (ALI), acute respiratory distress syndrome (ARDS) , ulcerative colitis, and to facilitate organ preservation for transplantation, to inhibit T lymphocyte activation, to prevent or treat chronic obstructive pulmonary disease (COPD) , and to prevent or treat pulmonary fibrosis (PF) .
  • diseases including acute lung injury (ALI), acute respiratory distress syndrome (ARDS) , ulcerative colitis, and to facilitate organ preservation for transplantation, to inhibit T lymphocyte activation, to prevent or treat chronic obstructive pulmonary disease (COPD) , and to prevent or treat pulmonary fibrosis (PF) .
  • COPD chronic obstructive pulmonary disease
  • PF pulmonary fibrosis
  • the present invention relates to a pharmaceutical composition substantially comprising an T216 and/or T174/T216 O-linked glycosylated FLINT analog polypeptide of the invention.
  • the present invention relates to a method to produce a FLINT analog resistant to proteolysis between position 218 and 219 of SEQ ID NO : 1 , alternatively between position 247 and 248 of SEQ ID NO: 3, comprising the step of increasing O-linked glycosylation at position T216 of SEQ ID NO:l (alternatively, T245 of SEQ ID NO:3).
  • the invention relates to a protease resistant FLINT analog produced by the method of enhancing O-linked glycosylation at position T216 of SEQ ID NO:l.
  • FLINT polypeptide undergoes proteolysis in vivo to produce at least two major peptide fragments.
  • One of the fragments consists of residues 1 through 218 of SEQ ID NO:l (alternatively residues 1 through 247 of SEQ ID NO:3), termed herein "FLINT metabolite;” the other consists of residues 219 through 271 of SEQ ID NO:l (alternatively residues 248 through 300 of SEQ ID NO: 3) .
  • Cleavage at the 218 position in vi tro can be achieved when native FLINT (SEQ ID NO:3), or mature FLINT (SEQ ID NO:l), is treated with a trypsin-like enzyme, for example, thrombin, trypsin or other serine protease.
  • a trypsin-like enzyme for example, thrombin, trypsin or other serine protease.
  • the invention relates to a FLINT analog that is resistant to proteolysis between positions 218 and 219 of SEQ ID NO : 1 , and/or between positions 247 and 248 of SEQ ID NO : 3 in vivo and/or in vi tro, said analog having enhanced O-linked glycosylation at T216.
  • the invention relates to a FLINT analog having enhanced O-linked glycosylation at T216, said analog comprising a polypeptide that is at least about 95% identical; alternatively at least 96% identical; alternatively at least 97% identical; alternatively at least 98% identical; alternatively still, at least 99% identical with residues 214 through 222 of SEQ ID NO : 1 and/or residues 243 through 251 of SEQ ID NO : 3.
  • the invention relates to a FLINT analog comprising one, two, three, four, five, or more amino acid substitution (s) , deletion(s), or addition(s) in the region comprising amino acids 214-222 of SEQ ID NO : 1 and/or amino acids 243-251 of SEQ ID NO: 3.
  • compositions of the present invention relate to O- linked glycosylated species of FLINT, N/O-linked glycosylated species of FLINT, and N-linked glycosylated species of FLINT, wherein one or more complex carbohydrate structures are linked to a threonine, serine, or asparagine residue.
  • an FLINT polypeptide comprises oligosaccharide O-linked to T174 of SEQ ID NO : 1.
  • the invention relates to a FLINT fragment, for example, the metabolite fragment comprising O- linked oligosaccharides.
  • the invention relates to FLINT fragments, for example, the metabolite fragment, comprising O-linked oligosaccharides said polypeptides complexed with a divalent metal cation.
  • the present invention relates to a FLINT fragment, for example, the metabolite fragment, comprising O-linked oligosaccharides wherein said oligosaccharides are covalently attached at T174 of SEQ ID NO:l (T203 of SEQ ID NO : 3 ) .
  • the invention relates to a FLINT fragment, for example, the metabolite fragment, comprising O-linked and N-linked oligosaccharides wherein said O-linked oligosaccharides are located at T174 of SEQ ID NO : 1 (T203 of SEQ ID NO: 3) and said N-linked oligosaccharides are located at N144 of SEQ ID NO : 1.
  • the present invention relates to a FLINT fragment, for example, the metabolite fragment, comprising N-linked oligosaccharide.
  • the invention relates to a FLINT fragment, for example, the metabolite fragment, comprising N-linked oligosaccharide at position N144 of SEQ ID NO:l.
  • the invention relates to a method for producing a FLINT polypeptide or fragment thereof comprising O-linked oligosaccharides at T174 and/or T216 of SEQ ID NO : 1 said method comprising expression of a vector encoding FLINT in a suitable mammalian cell line, for example, AVI2 , 293 EBNA, or CHO.
  • a suitable mammalian cell line for example, AVI2 , 293 EBNA, or CHO.
  • the invention relates to a method for producing a FLINT polypeptide or fragment thereof comprising N-linked and O-linked oligosaccharide at T174, and/or T216, and N-144 of SEQ ID NO : 1.
  • the invention relates to a composition substantially enriched in a FLINT polypeptide or fragment, for example the metabolite fragment, having O- linked oligosaccharide covalently linked to T174 of SEQ ID NO : 1.
  • the present invention relates to a composition substantially enriched in a FLINT polypeptide or fragment, for example the metabolite fragment, having N- linked oligosaccharide.
  • the invention relates to a composition substantially comprising a FLINT polypeptide or fragment, for example the metabolite fragment, having O- linked oligosaccharide covalently linked to T174 of SEQ ID NO:l, or T216 of SEQ ID NO : 1.
  • the invention relates to therapeutic and clinical uses of a FLINT polypeptide or fragment, for example the metabolite fragment, comprising O- linked oligosaccharides, or N-linked oligosaccharides, or N/O-linked oligosaccharides, to prevent or treat a disease or condition in a mammal in need of such prevention or treatmen .
  • a FLINT polypeptide or fragment for example the metabolite fragment, comprising O- linked oligosaccharides, or N-linked oligosaccharides, or N/O-linked oligosaccharides
  • the invention relates to therapeutic and clinical uses of a FLINT polypeptide or fragment, for example the metabolite fragment, of the present invention to prevent or treat a disease, for example, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), ulcerative colitis, and to facilitate organ preservation for transplantation, to inhibit T lymphocyte activation, to prevent or treat chronic obstructive pulmonary disease (COPD) , and to prevent or treat pulmonary fibrosis (PF) .
  • ALI acute lung injury
  • ARDS acute respiratory distress syndrome
  • COPD chronic obstructive pulmonary disease
  • PF pulmonary fibrosis
  • the present invention relates to a pharmaceutical composition comprising an N-linked glycosylated FLINT polypeptide or fragment, for example the metabolite fragment, of the invention.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising an N/O-linked glycosylated FLINT polypeptide or fragment, for example the metabolite fragment, of the invention.
  • the FLINT polypeptide of the invention has an amino acid sequence of SEQ ID NO : 1 , modified by: a) replacing tryptophan at position 53 with aspartic acid; b) replacing threonine at position 88 with proline; c) replacing alanine at position 107 with serine, aspartic acid, glutamic acid or threonine; d) replacing isoleucine at position 110 with threonine or glutamic acid; or e) replacing proline at position 104 with serine.
  • the FLINT polypeptide has an amino acid sequence of SEQ ID NO:l, modified by: a) replacing alanine at position 2 or position 12 with asparagine; b) replacing proline at position 25, position 38, position 126 or position 171 with asparagine; c) replacing arginine at position 35 with asparagine; d) replacing serine at position 37 with asparagine and proline at position 38 with any other naturally occurring amino acid; e) replacing serine at position 166 with asparagine ; f) replacing leucine at position 172 with asparagine; g) replacing aspartic acid at position 194 with asparagine ; h) replacing threonine at position 114 with asparagine and proline at position 115 with any naturally occurring amino acid; or i) replacing arginine at position 218 with asparagine.
  • the FLINT polypeptide has an amino acid sequence of SEQ ID NO:l, modified by: a) replacing asparagine at position 63 with tryptophan; b) replacing glycine at position 67 with aspartic acid and replacing alanine at position 94 or glycine at position 95 with tyrosine; c) replacing arginine at position 69 with glutamic acid; d) replacing arginine at position 82 with glutamic acid or threonine; e) replacing alanine at position 94 with tyrosine and replacing glycine at position 95 with aspartic acid; f) replacing phenylalanine at position 96 with glutamine; g) replacing alanine at position 101 with threonine; or h) replacing glycine at position 95 with aspartic acid.
  • the FLINT polypeptide has an amino acid sequence of SEQ ID NO:l, modified by: a) replacing arginine at position 10 with glutamine, asparagine, serine or threonine, provided that when the replacing amino acid is asparagine, then alanine at position 12 is optionally replaced with serine or threonine; b) replacing glutamic acid at position 13 with glutamine, asparagine, serine or threonine, provided that when the replacing amino acid is asparagine, then glycine at position 15 is optionally replaced with serine or threonine; c) replacing glutamic acid at position 16 with glutamine, asparagine, serine or threonine, provided that when the replacing amino acid is asparagine, then leucine at position 18 is optionally replaced with serine or threonine; d) replacing arginine at position 17 with glutamine, asparagine, serine or threonine, provided that when the replacing amino acid is
  • the FLINT of the present invention is a polypeptide having the ammo acid sequence of SEQ ID NO:l modified by: a) replacing alanme at position 2, 12, 107, 179 or 209 with threonine; b) replacing threonine at position 4 or 162 with alanine; c) replacing val e at position 1 or lsoleucme at position 110 with methionme; d) replacing glutamic acid at position 13 with aspartic acid; e) replacing arganme at position 17 with tryptophan; f) replacing alanme at position 75 with proline; g) replacing serine at positlone 102 with leucine; h) replacing glycine at position 169 with alanme;
  • the FLINT polypeptide has an ammo acid sequence of SEQ ID NO : 1 , modified by: a) replacing alanme at position 12 with asparagine and optionally replacing glutamic acid at position 13 with glutamine; b) replacing arginine at position 34 with asparagine and replacing aspartic acid at position 36 with threonine; c) replacing arginine at position 35 with asparagine and optionally replacing serine at position 37 with threonine; d) replacing serine at position 132 with asparagine and optionally replacing serine at position 134 with threonine; e) replacing aspartic acid at position 194 with asparagine and optionally replacing serine at position 196 with threonine; f) replacing arginine at position 35 and aspartic acid at position 194 with asparagine; g) replacing alanine at position 12 with asparagine, optionally replacing glutamic acid at position 13 with glutamine, replacing aspartic acid at
  • O-linked, and/or N-linked, and/or N/O-linked glycosylated species of FLINT can be produced in mammalian cells transfected with an expression vector that encodes FLINT.
  • Applicants have observed variation in the glycosylation pattern of FLINT molecules produced thereby, for example, in the fraction of polypeptides that are O- linked glycosylated at T174. The fraction of such species may vary depending upon cell culture conditions and on the particular cell type used as host.
  • a FLINT analog is expressed in CHO cells, from which about 40% of the FLINT polypeptide produced is glycosylated at T174.
  • SEQ ID NO : 2 Nucleic acid/cDNA encoding mature human FLINT.
  • SEQ ID NO: 3 Native human FLINT.
  • SEQ ID NO: 4 Human FLINT leader sequence.
  • Figure 2 Reverse phase chromatographic analysis of native FLINT glycosylation variants from AV12 cell line showing both N-linked glycosylation at Asn 144 and O-linked glycosylation at Thrl74 (peak A) and N-linked only (peak B) .
  • Figure 3. Reverse phase HPLC chromatogram of FLINT-A (N/O- linked native FLINT) and FLINT-B (N-linked native FLINT) .
  • Figure 4. Reverse phase HPLC chromatogram of FLINT metabolite purified after thrombin cleavage of wt FLINT using a C4 Vydac column.
  • Figure 5 RP-HPLC chromatogram of FLINT metabolite after concentration step.
  • Figure 6. Thermal denaturation of FLINT metabolite monitored by differential scanning calorimetry. The sample containing 0.2 mg/mL FLINT metabolite was dialyzed against PBS at pH 7.2.
  • FLINT analog refers to a FLINT molecule or sequence variant thereof having one or more amino acid sequence changes, e.g. substitution, addition, deletion, including variants that are resistant to proteolysis between positions 218 and 219 of SEQ ID N0:1 and/or positions 247 and 248 of SEQ ID NO : 3.
  • native FLINT refers to SEQ ID NO : 3.
  • mature FLINT refers to SEQ ID NO : 1.
  • FLINT is used herein generically to encompass native and mature FLINT, FLINT fragments, and analogs of FLINT having an altered amino acid sequence comprising one or more amino acid substitutions, deletions, or additions.
  • FLINT metabolite or “metabolite” refers to a fragment of FLINT comprising residues 1 to 218 of SEQ ID NO:l.
  • N-glycosyled polypeptide refers to polypeptides having one or more ⁇ XS/T motifs in which the nitrogen atom in the side chain amide of the asparagine is covalently bonded to a glycosyl group.
  • X refers to any naturally occurring amino acid residue except proline.
  • the "naturally occurring amino acids” are glycine, alanine, valine, leucine, isoleucine, proline, serine, threonine, cysteine, methionine, lysine, arganine, glutamic acid, asparatic acid, glutamine, asparagine, phenylalanine, histidine, tyrosine and tryptophan.
  • N-Glycosylated proteins are optionally O-glycosylated.
  • O-glycosyled polypeptide refers to polypeptides having one or more serines and/or threonine in which the oxygen atom in the side chain is covalently bonded to a glycosyl group.
  • O-Glycosylated proteins are optionally N- glycosylated .
  • substantially pure or substantially enriched” or “substantially comprising” is used herein to mean greater than 50%, preferably 80%-85%; most preferable at least 85% pure, i.e. separated from other proteins and/or other FLINT glycosylation species, and/or compounds and impurities.
  • a pharmaceutical composition substantially comprising FLINT having O-linked glycosylation would refer to a composition comprising a preparation of FLINT in which greater than 50%, preferably 80%-85%, more preferably at least 85% of said FLINT comprised O-linked glycosylated species.
  • nucleotide and amino acid abbreviations used herein are those accepted in the art and by the United States Patent and Trademark Office, as set forth in 37 C.F.R. 1.822 (b) (2) .
  • the invention further contemplates amino acid changes in the region from about position 214 through position 222 of SEQ ID NO : 1 or the comparable region of SEQ ID NO: 3 that increase the glycosylation at T216.
  • a single amino acid change is made within the region 214-222; alternatively, at least two changes are made within this region; alternatively, at least three changes are made within this region; alternatively, at least four changes are made within this region.
  • the invention relates to a method for producing a FLINT analog that is resistant to proteolysis between positions 218 and 219 of SEQ ID NO : 1 (positions 247 to 248 of SEQ ID NO : 3 ) , said method comprising the step of enhancing or increasing O-linked glycosylation at position T216 and/or T174 of SEQ ID NO : 1 (T245 and T203 of SEQ ID NO : 3 respectively).
  • Said enhancement or increase of O-linked glycosylation can be achieved by changing the cell line in which a recombinant FLINT is expressed. For example, the level of O-linked glycosylation of native FLINT was found to decrease in the order CHO >293 >AV12.
  • enhancement can be achieved by changing the conditions under which a recombinant cell line expressing FLINT is grown.
  • O-linked glycosylation at T216 can be enhanced by changing the arginine residue at position 218 to a neutral or negatively charged residue.
  • changing arginine, a positively charged amino acid, to a neutral or negatively charged amino acid increases the O-linked glycosylation at T216.
  • R218E is O-linked glycosylated at T216 to a greater extent than R218Q, which, in turn, is O-linked glycosylated at T216 to a greater extent than native FLINT (data not shown) .
  • FLINT is expressed in CHO cells from which about 50% of the FLINT polypeptide produced is N/O-linked glycosylated at T174.
  • Other cell lines such as AV12 and 293 produced less than 50% N/O-linked species .
  • O-linked, N-linked, and N/O-linked FLINT polypeptides can be separated from each other and from other glycosylation species of FLINT by a variety of suitable purification techniques, for example, reverse phase HPLC and polyacrylamide gel electrophoresis .
  • suitable purification techniques for example, reverse phase HPLC and polyacrylamide gel electrophoresis .
  • Different glycosylation species of FLINT can be resolved by a variety of analytical and preparative techniques.
  • different glycosylation species of FLINT prepared from a mammalian cell line, for example, transfected AV12 cells can be separated by PAGE or RP-HPLC revealing at least two peaks (See Figure 2) .
  • O-linked FLINT polypeptides are glycosylated at T174 and/or T216.
  • O-linked glycosylated FLINT of the invention may also be N-linked glycosylated at position N144.
  • FLINT polypeptides that are expressed in mammalian cells such as 293 EBNA, AV12 , and CHO are substantially glycosylated at N144, and partially O-linked glycosylated at T174 and T216.
  • the fraction of FLINT molecules that are O- linked glycosylated at T216 tends to be less than at T174.
  • the O-linked glycosylated FLINT polypeptides of the invention comprise a plurality of O-linked oligosaccharide structures (See Figure 1) . Predominant oligosaccharide structures at T216 and T174 on FLINT include GalNAc, Galactose, and NeuAc .
  • the invention described herein relates, in one embodiment, to FLINT polypeptides having increased stability, said polypeptides having O- linked oligosaccharides at T174 and/or T216, and N-linked oligosaccharides at N144.
  • said FLINT is O-linked glycosylated at T174 and/or T216.
  • the invention provides a compound substantially comprising T216 O-linked glycosylated FLINT, alternatively an N-linked FLINT, wherein said glycosylation occurs at, for example, T174 and/or T216, complexed with a divalent metal cation.
  • the invention provides a compound comprising an N-linked FLINT protein, for example, N144 complexed with a divalent metal cation.
  • the invention provides a compound comprising an N/O-linked FLINT protein, for example, N144/T174, N144/T174/T216 , or N144/T216, complexed with a divalent metal cation.
  • compositions comprising O-linked, or N-linked, or N/O-linked glycosylated FLINT and divalent cation (s) are provided. These compositions may be used in depot formulations for therapeutic application.
  • FLINT compositions comprise O-linked, or N-linked, or N/O- linked glycosylated FLINT polypeptides complexed with one or more divalent metal cations.
  • Suitable divalent metal cation include, for example, Zn +2 , Mn +2 , Fe +2 , Co +2 , Cd +2 , Ca +2 , Ni +2 and the like.
  • Such compositions may comprise a single species of metal ion or a combination of two or more species of divalent metal cations.
  • Preferred compounds comprise a single species of metal cation, most preferably Zn +2 .
  • the divalent metal cation is in excess; however, the molar ratio of at least one molecule of a divalent metal cation for each ten molecules of FLINT is operable.
  • the compounds comprise from 1 to 100 divalent metal cations per molecule of FLINT.
  • the compounds may be amorphous or crystalline solids.
  • metal cations are any form of a divalent metal cation that is available to form a complex with a molecule of a FLINT protein of the present invention.
  • the metal cation may be added in solid form or as a solution.
  • Several different cationic salts can be used in the present invention. Representative examples of metal salts include the acetate, bromide, chloride, fluoride, iodide and sulfate salt forms. The skilled artisan will recognize that there are many other metal salts which also might be used in the production of the compounds of the present invention.
  • zinc acetate or zinc chloride is used to create the zinc-FLINT protein compounds of the present invention.
  • the divalent metal cationic salt is zinc chloride.
  • the present invention relates further to the use of the FLINT polypeptides of the invention to inhibit apoptosis and/or T cell activation.
  • T cell activation can be chronically suppressed when advantageous, for example, following organ transplantation to prevent rejection, in the treatment of autoimmune diseases, and in treating systemic inflammatory responses.
  • FLINT polypeptides of the invention can be produced by recombinant techniques or by direct chemical synthesis, well known to the skilled artisan. See . e . g. K. Struhl, "Reverse biochemistry: Methods and applications for synthesizing yeast proteins in vi tro, " Meth . Enzymol . 194, 520-535.
  • site-directed mutagenesis is used to introduce defined changes into the region 214-222 of SEQ ID NO:l or the comparable region of SEQ ID NO: 3.
  • FLINT polypeptides also include modified derivatives thereof in which one or more polyethylene glycol groups (hereinafter "PEG" groups) are bonded to the N-terminus or to amine groups or thiol groups in the amino acid side chain (s) .
  • PEG groups generally have a molecular weight between about 5000 and 20,000 atomic mass units. Procedures for preparing PEGylated polypeptides are disclosed in Mumtaz and Bachhawat , Indian Journal of Biochemistry and Biophysics 28:346 (1991) and Franciset al . , International Journal of Hematology 68 : 1 (1998), the entire teachings of which are incorporated herein by reference.
  • Another embodiment of the invention relates to a fusion protein comprising an O-linked FLINT polypeptide, or an N- linked FLINT polypeptide, or an N/O-linked FLINT polypeptide.
  • Preferred embodiments include T174 , T216, T174/T216, N144, T174/N144, T216/N144, T174/T216/N144.
  • Fusion protein denotes a hybrid protein molecule not found in nature comprising a translational fusion or enzymatic fusion in which two or more different proteins or fragments thereof are covalently linked on a single polypeptide chain.
  • Human serum albumin and the C-terminal domain of thrombopoietin are examples of proteins which could be fused with a FLINT polypeptide of the invention.
  • a fusion protein of the present invention comprises two protein segments fused together by means of a peptide bond.
  • the first protein segment consists of at least 6, 7, 8, 9, 10, 12, 15, 20, 25, 30, 35, 40, 50, 75, 100, 125, 150, 175, 200, 225, 250, or 271 contiguous amino acid residues of an FLINT polypeptide of the present invention (i.e.
  • the first protein can alternatively be a full length protein of the present invention and/or an N-terminal or C-terminal fragment thereof .
  • the second protein of a FLINT fusion protein of the invention can be a full length protein or a protein fragment.
  • Proteins commonly used in fusion proteins include B-galactosidase , B-glucuronidase, green fluorescent protein (GFP) , thrombopoietin (TPO) , glutathione-S-transferase (GST) , luciferase, horseradish peroxidase, and chloramphenicol acetyltransferase (CAT) .
  • Epitope tags can be used in fusion protein constructions including histidine (His) tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin tags.
  • Other fusion constructions can include maltose binding protein, S-tag, Lex A DNA binding domain, GAL4 DNA binding domain fusions, and herpes simplex virus BP16 protein fusions.
  • nucleic acids encoding a FLINT (native or analog) of the present invention can be prepared synthetically. For analogs, this can be achieved by mutating a nucleic acid template that encodes native FLINT, e.g. introducing appropriate point mutations into a cDNA encoding FLINT using any number of suitable mutagenic techniques known to the skilled artisan.
  • said nucleic acids can be prepared synthetically de novo based on knowledge of the genetic code and the particular analog of SEQ ID NO : 1 or SEQ ID NO: 3 desired. Codon preference may be taken into account when designing a suitable nucleic acid.
  • a FLINT cDNA can be synthesized by RT-PCR using conventional techniques.
  • PolyA RNA is prepared from a tissue known to express the FLINT gene (e.g. human lung), using standard methods.
  • First strand FLINT cDNA synthesis is achieved in a reverse transcriptase reaction using a FLINT sequence derived "downstream" primer.
  • a commercially available kit such as GENEAMP by Perkin Elmer may be employed.
  • FLINT specific forward and reverse primers are used to amplify the cDNA.
  • the amplified sample may be analyzed by agarose gel electrophoresis to check the length of the amplified fragment .
  • FLINT cDNA generated in this manner is used as a template for introducing appropriate point mutations (i.e.
  • Nucleic acid molecules of the present invention can be in the form of RNA, such as mRNA, hnRNA, or any other form, or in the form of DNA, including, but not limited to, cDNA and genomic DNA obtained by cloning or produced synthetically, or any combination thereof.
  • the DNA can be triple-stranded, double-stranded or single-stranded, or any combination thereof. Any portion of at least one strand of the DNA or RNA can be the coding strand, also known as the sense strand, or it can be the non-coding strand, also referred to as the anti-sense strand.
  • “Host cell” refers to any eucaryotic, procaryotic, or other cell or pseudo cell or membrane-containing construct that is suitable for propagating and/or expressing an isolated nucleic acid that is introduced into a host cell by any suitable means known in the art (e.g., transformation or transfection, or the like) , or induced to express an endogenous polydeoxynucleic acid.
  • the cell can be part of a tissue or organism, isolated in culture or in any other suitable form.
  • eucaryotic expression systems such as yeast, insect cell lines, plant and mammalian cells, are known to those of skill in the art.
  • Nucleic acid sequences encoding a FLINT polypeptide of the present invention can be ligated to various expression vectors for use in transfecting cell cultures of, for instance, mammalian, insect, or plant origin.
  • Preferred cell cultures useful for the production of FLINT polypeptides are mammalian cells. Mammalian cell monolayers or suspensions may be used. A number of suitable mammalian host cell lines have been developed in the art, including the AV12, 293 EBNA, HEK293, BHK21, and CHO cell lines.
  • Expression vectors for these cell lines can include expression control sequences, such as an origin of replication, a promoter (e.g., the CMV promoter, a HSV tk promoter or pgk (phosphoglycerate kinase) promoter), an enhancer, and processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites (e.g., bovine growth hormone poly A addition site), and transcriptional terminator sequences.
  • a promoter e.g., the CMV promoter, a HSV tk promoter or pgk (phosphoglycerate kinase) promoter
  • processing information sites such as ribosome binding sites, RNA splice sites, polyadenylation sites (e.g., bovine growth hormone poly A addition site), and transcriptional terminator sequences.
  • the expression of isolated nucleic acids encoding a FLINT analog of the present invention will typically be achieved by operably linking a DNA or cDNA encoding an analog to a promoter (which is either constitutive or inducible) , followed by incorporation into an expression vector.
  • the vectors can be suitable for replication and integration in either procaryotes or eucaryotes.
  • To obtain high level expression of a cloned gene it is desirable to construct expression vectors that contain a promoter to direct transcription, a ribosome binding site for translational initiation, and a transcription/translation terminator.
  • modifications may be made to facilitate the cloning, expression, or incorporation of the targeting molecule into a fusion protein.
  • modifications are well known to those of skill in the art and include, for example, a methionine added at the amino terminus to provide an initiation site, or additional amino acids (e.g., poly His) placed on either terminus to create conveniently located restriction sites or termination codons or purification handle sequences.
  • Protein Purification A FLINT polypeptide of the present invention comprising
  • N-linked, and/or O-linked, an/or N/O-linked oligosaccharides can be recovered and purified from recombinant cells that express said polypeptide by any suitable method, well-known to the skilled artisan including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, and immobilized metal ion affinity chelating chromatography, "IMAC," as taught in U.S. Patent 4,569,974 herein incorporated by reference, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography.
  • species of FLINT polypeptides of the present invention are separated and purified by reverse phase high performance liquid chromatography ("RP-HPLC").
  • FLINT polypeptides inhibit the binding of Fas to FasL and LIGHT to LT ⁇ R and TR2/HVEM receptors, and can be used to treat or prevent a disease and/or condition that may be associated with such binding interactions.
  • FLINT polypeptides of the present invention are clinically and/or therapeutically useful for treating and/or preventing a plurality of diseases including Rheumatoid arthritis (Elliott et al . , Lancet 344:1105-10 (1994)), fibroproliferative lung disease, fibrotic lung disease, acute lung injury, acute respiratory distress syndrome, HIV (Dockrell et al . , J. Clin . Invest . 101:2394-2405 (1998)), Ischemia (Sakurai et al . 1998 Brain Res 797:23-28), Brain trauma/injury (Ertel et al . 1997 J Neuroimmunol 80:93-6), chronic renal failure (Schelling et al .
  • diseases including Rheumatoid arthritis (Elliott et al . , Lancet 344:1105-10 (1994)), fibroproliferative lung disease, fibrotic lung disease, acute lung injury, acute respiratory distress syndrome, HIV (D
  • an "effective amount" of a FLINT polypeptide is an amount which achieves a desired therapeutic or prophylactic effect in a subject with a disease, or in a method of the invention, that may be associated with aberrant Fas/Fas
  • an "effective amount" of a FLINT polypeptide is a quantity sufficient to achieve a desired therapeutic and/or prophylactic effect in a subject with inflammation caused by Fas Ligand induced neutrophil activation or any of the other aforementioned diseases associated with aberrant Fas Ligand activity.
  • the amount of FLINT administered to the individual will depend on the type and severity of the disease and on the characteristics of the individual, such as general health, age, sex, body weight and tolerance to drugs. It will also depend on the degree, severity and type of disease. The skilled artisan will be able to determine appropriate dosages depending on these and other factors.
  • the total pharmaceutically effective amount of FLINT of the present invention administered parenterally per dose will be in the range of about 1 ⁇ g/kg/day to 10 mg/kg/day of patient body weight, particularly 2 mg/kg/day to 8 mg/kg/day, more particularly 2 mg/kg/day to 4 mg/kg/day, even more particularly 2.2 mg/kg/day to 3.3 mg/kg/day, and finally 2.5 mg/kg/day, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day.
  • the FLINT of the present invention are typically administered at a dose rate of about 1 ⁇ g/kg/hour to about 50 ⁇ g/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini -pump.
  • An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.
  • compositions containing a FLINT polypeptide of the present invention may be administered orally, rectally, intracranially, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, drops or transdermal patch) , transdermally, intrathecally, bucally, or as an oral or nasal spray.
  • pharmaceutically acceptable carrier is meant a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
  • parenteral as used herein includes, but is not limited to, modes of administration which include intravenous, intramuscular, intraperitoneal , intrasternal , subcutaneous and intraarticular injection, infusion and implants comprising FLINT.
  • the FLINT polypeptides of the present invention are formulated generally by mixing at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion) , with a pharmaceutically acceptable carrier, i.e., one that is non- toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.
  • a pharmaceutically acceptable carrier i.e., one that is non- toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.
  • the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides.
  • the formulations are prepared by contacting the FLINT of the present invention uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation.
  • the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes .
  • the carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability.
  • Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides ; proteins, such as serum albumin, gelatin, or immunoglobulins ; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides , disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.
  • buffers such as phosphat
  • the FLINT polypeptides of the present invention are typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of salts of the FLINT analogs of the present invention.
  • FLINT variant R218Q was constructed by mutagenic PCR starting from a wild-type FLINT template. See e . g. Saiki R. K. et al . Science 239:487-491 (1988), and "Current Protocols in Molecular Biology", Vol 1, section 8.5.7 (John Wiley and Sons, Inc. publishers) .
  • the R218Q mutant substitutes an arginine residue found at amino acid 218 with glutamine.
  • the mutagenic PCR process utilized a SOEing reaction (i.e. Strand Overlap Extension) to create specific mutations in the native FLINT template for the purpose of changing the amino acid sequence at position 218, and further for introducing restriction enzyme tags for identification purposes.
  • SOEing reaction i.e. Strand Overlap Extension
  • SOEing reactions require the use of four primers, two in the forward orientation (termed A, SEQ ID NO: 5, and C, SEQ ID NO: 7) and two in the reverse orientation (termed B, SEQ ID NO : 6 and D, SEQ ID NO: 8) .
  • the SOEing reaction amplifies a nucleic acid sequence (e.g. gene sequence) in two stages. The first step is to amplify "half" the gene by performing an A to B reaction followed by a separate C to D reaction. In constructing the R218Q mutant, the B and C primers were targeted to the same area of the gene but on opposite strands . Mismatch priming from both oligonucleotide primers institutes the mutation. After these two reactions were completed, the products were isolated and mixed for use as the template for the A to D reaction, which yields the desired mutated product.
  • the primers involved in the cloning of R218Q were:
  • Primer A CF 107 (39 nt) GCACCAGGGTACCAGGAGCTGAGGAGTGTGAGCGTGCCG
  • Primer B CF 111 (44 nt) TCAGCTGCAAGGCGGCGCGCCCCGCTTGTGGTGTCGGACCCCAG
  • Primer C CF 112 (44 nt) GGGGTCCGACACCACAAGCGGGGCGCGCCGCCTTGCAGCTGAAG
  • Primer D CF 110 (43 nt) GCACAGAATTCATCAGTGCACAGGGAGGAAGCGCTCACGGACG
  • the 311 base pair amplified fragment carrying the R218Q mutation was sub-cloned using a 5' Kpnl site (GGTACC) and a 3' EcoRI site (GAATTC) .
  • the native FLINT sequence has a naturally occurring internal Kpnl site around amino acid position 176.
  • the EcoRI site was introduced for sub-cloning purposes and lies downstream of the stop codons . These sites are underlined in primers A and D respectively.
  • the 311 bp fragment was incorporated into the full length FLINT sequence. This was accomplished through the following steps:
  • the 311 bp fragment was placed into an intermediate vector, pCR2.1- TOPO, which utilizes the adenine overhangs established after PCR for ligation.
  • a Kpnl to EcoRI digestion removed a 289 bp fragment. (Note: the size of the PCR fragment decreased from 311 bp to 289 bp due to the digestion) .
  • the mutated fragment was used to replace the corresponding segment in the wild type FLINT gene by directional ligation.
  • Fragment 1 6070 bp
  • the 6070 bp fragment carrying the FLINT gene was isolated and ligated with the 289 bp PCR product removed from the pCR 2.1-TOPO vector to create R218Q/pJB03. Positive clones were identified by restriction digestion and subsequently confirmed by sequence analysis.
  • the R218Q analog contained in R218Q/pJB03 was shuffled into the pIG3 vector by means of a Nhel to Xbal undirected ligation.
  • R218Q/pJB03 was digested with Nhel to Xbal to yield fragments of 932 and 5427 bp .
  • the 932 bp FLINT R218Q containing fragment was isolated.
  • the 932 bp Nhel and Xbal fragment of R218Q was ligated with the 8510 bp linearized pIG 3 vector to generate clones in both forward and inverse orientations .
  • Mammalian Cells A bicistronic expression vector was constructed by inserting into mammalian expression vector pGTD (Gerlitz, B. et al . , 1993, Biochemical Journal 295:131) a PCR fragment encoding an "internal ribosome entry site" /enhanced green fluorescent polypeptide (IRES/eGFP) .
  • the new vector, designated pIG3 contains the following sequence landmarks: the Ela-responsive GBMT promoter (D. T. Berg et al . , 1993 BioTechniques 14:972; D.T. Berg et al .
  • MCS multiple cloning site
  • IRES IRES sequence from encephalomyocarditis virus (EMCV)
  • EMCV encephalomyocarditis virus
  • eGFP eGFP coding sequence
  • dhfr murine dihydrofolate reductase
  • the FLINT cDNA orientation and nucleotide sequence was confirmed by restriction digest and double stranded sequencing of the insert.
  • the approximately 900 base pair amplified FLINT analog PCR product was digested with restriction endonucleases Nhel and Xbal, respectively, to generate a fragment bearing Nhel and Xbal sticky ends. This fragment was subsequently ligated into a unique Xbal site of pIG3 to generate recombinant plasmid pIG3 -FLINT.
  • the insert encoding FLINT can be modified at the C-terminus of the analog to introduce a cleavable hexahistidine (His6) cassette to facilitate analog purification.
  • the recombinant plasmid of Example 2 carries the FLINT gene and encodes resistance to methotrexate .
  • the construct contains a gene encoding a fluorescent polypeptide, GFP, on the same transcript and immediately 3' to the FLINT gene. Since high level expression of GFP would require a high level of expression of the FLINT-GFP mRNA, highly fluorescent clones have a greater probability of producing high levels of FLINT.
  • AV12 RGT18 cells are transfected using a calcium phosphate procedure with recombinant plasmid pIGl .
  • Cells resistant to 250 nM methotrexate are selected and pooled.
  • the pool of resistant clones is subjected to fluorescence assisted cell sorting (FACS) , and cells having fluorescence values in the top 5% of the population are sorted into a pool and as single cells.
  • High fluorescence pools are subjected to two successive sorting cycles. Pools and individual clones from the first and second cycles are analyzed for FLINT production by ELISA. Pools or clones expressing FLINT at the highest level are used for scale-up and FLINT purification.
  • FACS fluorescence assisted cell sorting
  • mFLINT Large scale production of mature FLINT (mFLINT) was carried out by growing stable clones of AV12 RGT 18 cells transfected with pIG3 -FLINT in several 10 liter spinners. After reaching confluency, cells were further incubated for 2-3 more days to secrete maximum amount of mFLINT into the growth medium.
  • Medium containing mFLINT was adjusted to 0.1 % CHAPS and concentrated in an Amicon ProFlux M12 tangential filtration system to 350 ml. The concentrated media was adjusted to pH 6.0 and passed over a SP Sepharose Fast Flow (Pharmacia, 500 ml) at a flow rate of 7 ml/min.
  • the bound mFLINT was separated into a predominantly N- linked species, and a predominantly N/O-linked mFLINT species by elution with a linear gradient 0 % to 50 % CH 3 CN/O.I % TFA over 10 column volumes followed by a linear gradient from 50 % to 90 % CH 3 CN/0.1 % TFA over 1 column volumne .
  • Fractions containing N/O-linked mFLINT and N- linked mFLINT were separately pooled, concentrated under vacuum to approximately 4 ml and an equal volume of PBS, 0.5 M NaCl, 10 % glycerol, 100 mM Tris, 50 mM EDTA, pH 7.0 was added.
  • the purified samples were dialyzed against four liters of PBS, 0.5 M NaCl , 10 % glycerol, 1 mM EDTA, pH 7.4 three times and four liters of PBS, 0.5 M NaCl, 10 % glycerol, pH 7.4 three times.
  • Substantially pure fractions obtained in this fashion contain either predominantly N/O- linked or N-linked mFLINT. Analysis by SDS-PAGE revealed these fractions to be greater than 85% pure.
  • the N-terminal sequence of mFLINT was confirmed on the purified polypeptides.
  • LC-MS was performed on the polypeptides to confirm the location of the glycans .
  • FLINT analogs can be quantitated in crude media of transfected cells and during purification procedure by a developed FLINT ELISA.
  • ELISA uses anti-FLINT polyclonal antibody TKD-028 (1494 ) as a capture antibody and biotinylated anti-FLINT TKD-076A as a primary antibody in a "sandwich” assay.
  • ELISA is developed by streptavidin derivatized horse radish peroxidase (SA-HRP) using OPD as a substrate and monitoring the absorbance at 490 mn. The useful range of such an ELISA is from 0.2 - 20 ng/ml .
  • MicroCalorimeter using VPViewer software and Origin DSC software for data analysis The matched sample and reference cells had a working volume of 0.5 mL .
  • FLINT samples were dialyzed against buffer containing 25 mM Tris, 150 mM NaCl at pH 6.8 overnight and the concentration of protein was determined by UV absorbance at 277 nm using extinction coefficient of 0.786 for 1 mg/mL protein sample in 1-cm pathlength cell.. Buffer was also run overnight in both cells to establish a thermal history prior to sample runs. Proteins were then diluted to approximately 0.15 mg/mL, and the dialysate was used as the reference solution.
  • FLINT R218Q Large scale production of FLINT R218Q is carried out by first growing stable pIGl-R218Q-containing AV12 RGT 18 cells in several 10 liter spinners. After reaching confluency, cells are further incubated for 2-3 more days to secrete maximum amount of FLINT analog into media.
  • Medium containing FLINT analog is adjusted to 0.1 % CHAPS and concentrated in an Amicon ProFlux M12 tangential filtration system to 350 ml. The concentrated medium is adjusted to pH 6.0 and passed over a SP Sepharose Fast Flow (Pharmacia, 500 ml) at a flow rate of 7 ml/min.
  • the column is washed with buffer A (20 mM MOPS, 0.1 % CHAPS, pH 6.0) until the absorbance (280 nm) returns to baseline and the bound polypeptides are eluted with a linear gradient from 0 to 1 M NaCl (in buffer A) developed over four column volumes.
  • Fractions containing FLINT are pooled and passed over Vydac C4 column (100 ml) equilibrated with 0.1 % TFA/H 2 0 at a flow rate of 10 ml/min.
  • the bound FLINT analog is separated into N-linked and O-linked FLINT analog and N-linked FLINT analog by elution with a linear gradient 0 % to 50 % CH 3 CN/0.1 % TFA over 10 column volumes followed by a linear gradient from 50 % to 90 % CH 3 CN/0.1 % TFA over 1 column volume.
  • Fractions containing N- and O- linked FLINT and N-linked FLINT are pooled separately, concentrated under vacuum to approximately 4 ml and an equal volume of PBS, 0.5 M NaCl, 10 % glycerol, 100 mM Tris, 50 mM EDTA, pH 7.0 is added.
  • the purified samples are dialyzed against four liters of PBS, 0.5 M NaCl, 10 % glycerol, 1 mM EDTA, pH 7.4 three times and four liters of PBS, 0.5 M NaCl, 10 % glycerol, pH 7.4 three times.
  • Fr ⁇ .ctions containing N- and O-linked versus N-linked FLINT are analyzed by SDS-PAGE.
  • the N- terminal sequence of FLINT is confirmed on the purified polypeptides.
  • LC-MS is performed on the polypeptides to confirm the location of the glycans .
  • EXAMPLE 8 Use of O-linked Glycosylated FLINT to Treat ALI Patient A 55 year-old male presents to the emergency department unconscious. His family states that he was being treated as an outpatient for bronchitis for the past few days but worsened despite antibiotics. He has no relevant past history and his only medication was a third generation oral cephalosporin. Physical examination reveals an obtunded, cyanotic male who is hypotensive, tachypneic, and tachycardic, and who has bilateral lung congestion consistent with pulmonary edema. There is no evidence of congestive heart failure.
  • Tests reveal hypoxemia (based on Pa02/Fi02) and bilateral lung infiltrates without cardiomegaly, consistent with a diagnosis of acute lung injury. Based on the history it is concluded that the lung injury was a direct result of community-acquired pneumonia, and that the patient met the hypoxemia criteria for ALI within the last 12 hours. Ventilation measures include use of PEEP and low tidal volume. As soon as adequate oxygenation is confirmed, treatment with O-linked glycosylated FLINT is initiated in the ER as an iv bolus of
  • EXAMPLE 9 Effect of ZnCl 2 on thermal stability of FLINT Analog
  • the conformational stability of FLINT analog R218Q in the presence or absence of ZnCl 2 is monitored by differential scanning calorimetry (DSC) .
  • Data is collected on a VP-DSC MicroCalorimeter using VPViewer software and Origin DSC software for data analysis.
  • the matched sample and reference cells have a working volume of 0.5 mL .
  • FLINT samples are dialyzed against buffer containing 25 mM Tris, 150 mM NaCl at pH 6.8 overnight and the concentration of protein determined by UN absorbance at 277 nm using extinction coefficient of 0.786 for 1 mg/mL protein sample in 1 cm path length cell.
  • Buffer is also run overnight in both cells to establish a thermal history prior to sample runs. Proteins are diluted to approximately 0.15 mg/mL, and the dialysate is used as the reference solution. 2 ul or 4 ul of ZnCl 2 at 5 mM is added to 1 mL protein sample to obtain 10 uM and 20 uM ZnCl 2 concentration, respectively. After degassing, sample and reference are loaded in cells with 2.5 mL needle through a filling funnel. Pressure is kept at approximately 30 psi . with a pressure cap. Data is collected between 5° and 100°C. Thermal scan of FLINT analog with or without ZnCl 2 is taken. Data is analyzed to obtain the midpoint of thermal transition (T m ) .
  • FLINT analog sample contains two populations of molecules, one containing only N-linked glycosylation at Asnl44, the other containing both N-linked glycosylation and O-linked glycosylation at T174 and/or T216. These two populations of molecules are separated by RP-HPLC. The data suggest that ZnCl 2 has a stabilizing effect on FLINT analog containing additional O-linked glycosylation compared to FLINT only containing N-linked glycosylation.
  • EXAMPLE 10 Production of the FLINT Metabolite FLINT was purified from AV12 RGT 18 cells transfected with a recombinant vector carrying a FLINT cDNA (SEQ ID NO : 1 or SEQ ID NO : 3 ) .
  • This material was cleaved with thrombin at a weight ratio of 1 to 100 (thrombin to FLINT) for three hours at room temperature, dialyzed against 20 mM MOPS, 0.1% CHAPS, pH 6.5, and passed over a SP Sepharose column at a flow rate of 1 ml/min. The column was washed with buffer A (20 mM MOPS, 0.1% CHAPS, pH 6.5) until the absorbance returned to baseline.
  • the bound metabolite (amino acids 1 to 218 of SEQ ID NO:l) was eluted with a linear gradient from 0 to 300 mM NaCl (in buffer A) developed over 10 min. followed by a linear gradient for 0.3 to 0.5 M (in buffer A) . Fractions were analyzed by SDS-PAGE and mass spectrometry. Fractions containing only the FLINT metabolite (1-218) were pooled and concentrated in Millipore Ultrafree centrifugal filter. The concentrated metabolite (1-218) was again analyzed by SDS-PAGE and mass spectrometry to assess purity. N-terminal sequencing confirmed the identity of the purified material as FLINT metabolite (1- 218) .
  • FLINT Glycosylation When FLINT was injected subcutaneously or intravenously in mice, a metabolite containing amino acids 1-218 of FLINT was formed. This metabolite can also be generated using thrombin cleavage in vi tro .
  • FLINT produced as in Examples 2 through 4 was treated with thrombin and the metabolite produced thereby analyzed by reverse phase HPLC and differential scanning calorimetry . As shown in Figure 4, FLINT metabolite contains two species when analyzed by RP-HPLC, N-linked and N/O-linked.
  • Metabolite containing N/O-linked glycosylation is more stable than N-linked species, as shown by RP-HPLC.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des polypeptides FLINT glycosylés à liaison O qui comprennent des oligosaccharides à liaison O à la position d'acide aminé 174 et/ou 216 de SEQ ID NO: 1 (c'est-à-dire FLINT mature), des compositions desdits polypeptides, qui peuvent comprendre des cations métalliques bivalents, des utilisations cliniques et thérapeutiques desdits polypeptides, et des formulations pharmaceutiques comprenant lesdits polypeptides.
PCT/US2000/030166 1999-12-07 2000-11-29 Amelioration de la stabilite de la proteine flint (fas ligand inhibitory protein) par glycosylation a liaison o Ceased WO2001042463A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP00982080A EP1244783A1 (fr) 1999-12-07 2000-11-29 AMELIORATION DE LA STABILITE DE LA PROTEINE FLINT ( i FAS LIGAND INHIBITORY PROTEIN /i ) PAR GLYCOSYLATION A LIAISON O
AU19152/01A AU1915201A (en) 1999-12-07 2000-11-29 Improving stability of flint through o-linked glycosylation

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US16941299P 1999-12-07 1999-12-07
US16936799P 1999-12-07 1999-12-07
US16938199P 1999-12-07 1999-12-07
US60/169,367 1999-12-07
US60/169,381 1999-12-07
US60/169,412 1999-12-07
US19143000P 2000-03-23 2000-03-23
US60/191,430 2000-03-23

Publications (1)

Publication Number Publication Date
WO2001042463A1 true WO2001042463A1 (fr) 2001-06-14

Family

ID=27496833

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030166 Ceased WO2001042463A1 (fr) 1999-12-07 2000-11-29 Amelioration de la stabilite de la proteine flint (fas ligand inhibitory protein) par glycosylation a liaison o

Country Status (3)

Country Link
EP (1) EP1244783A1 (fr)
AU (1) AU1915201A (fr)
WO (1) WO2001042463A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1336619A3 (fr) * 2002-02-19 2003-12-10 Millenium Pharmaceuticals, Inc. Combinaison d'un inhibiteur HVEM-LIGHT et d'un agent immunosuppressif pour le traitement ou la prévention des maladies immunes
US7186800B1 (en) 1997-01-14 2007-03-06 Human Genome Sciences, Inc. Tumor necrosis factor 6α and 6β
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
EP2207597B1 (fr) 2007-09-18 2020-02-19 La Jolla Institute for Allergy and Immunology Inhibiteurs de la voie light utilisés dans le traitement de l'asthme, de l'inflammation des poumons et des voies respiratoires, de la fibrose pulmonaire interstitielle

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999014330A1 (fr) * 1997-09-18 1999-03-25 Genentech, Inc. HOMOLOGUE DU TNFR APPELE POLYPEPTIDE DcR3
WO1999050413A2 (fr) * 1998-03-30 1999-10-07 Eli Lilly And Company APPLICATIONS THERAPEUTIQUES DE POLYPEPTIDES mFLINT MURS, OU DE OPG3 EN TANT QUE MEMBRE DE LA SUPERFAMILLE DU RECEPTEUR DU TNF
WO2000052028A1 (fr) * 1999-03-04 2000-09-08 Human Genome Sciences, Inc. Recepteurs du facteur de necrose tumorale 6 alpha et 6 beta
WO2000053755A2 (fr) * 1999-03-08 2000-09-14 Genentech, Inc. Compositions et procedes pour le traitement de tumeur
WO2000058465A2 (fr) * 1999-03-30 2000-10-05 Eli Lilly And Company Analogues polypeptidiques de flint

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999014330A1 (fr) * 1997-09-18 1999-03-25 Genentech, Inc. HOMOLOGUE DU TNFR APPELE POLYPEPTIDE DcR3
WO1999050413A2 (fr) * 1998-03-30 1999-10-07 Eli Lilly And Company APPLICATIONS THERAPEUTIQUES DE POLYPEPTIDES mFLINT MURS, OU DE OPG3 EN TANT QUE MEMBRE DE LA SUPERFAMILLE DU RECEPTEUR DU TNF
WO2000052028A1 (fr) * 1999-03-04 2000-09-08 Human Genome Sciences, Inc. Recepteurs du facteur de necrose tumorale 6 alpha et 6 beta
WO2000053755A2 (fr) * 1999-03-08 2000-09-14 Genentech, Inc. Compositions et procedes pour le traitement de tumeur
WO2000058465A2 (fr) * 1999-03-30 2000-10-05 Eli Lilly And Company Analogues polypeptidiques de flint

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186800B1 (en) 1997-01-14 2007-03-06 Human Genome Sciences, Inc. Tumor necrosis factor 6α and 6β
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
US7534428B2 (en) 1997-01-14 2009-05-19 Human Genome Sciences, Inc. Antibodies to tumor necrosis factor receptors 6α and 6β
US7709218B2 (en) 1997-01-14 2010-05-04 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α and 6β
EP1336619A3 (fr) * 2002-02-19 2003-12-10 Millenium Pharmaceuticals, Inc. Combinaison d'un inhibiteur HVEM-LIGHT et d'un agent immunosuppressif pour le traitement ou la prévention des maladies immunes
EP2207597B1 (fr) 2007-09-18 2020-02-19 La Jolla Institute for Allergy and Immunology Inhibiteurs de la voie light utilisés dans le traitement de l'asthme, de l'inflammation des poumons et des voies respiratoires, de la fibrose pulmonaire interstitielle

Also Published As

Publication number Publication date
AU1915201A (en) 2001-06-18
EP1244783A1 (fr) 2002-10-02

Similar Documents

Publication Publication Date Title
US7855269B2 (en) Method for treating inflammation
US20040014948A1 (en) Single-chain antagonist polypeptides
US20080108560A1 (en) Heterologous G-Csf Fusion Proteins
JP3946638B2 (ja) 生体内エリスロポエチン活性が増強された融合蛋白質
CN108473546B (zh) Mg53突变体及其制备方法和用途
US7084253B2 (en) Protease-activated receptor PAR4 (ZCHEMR2)
EP1244783A1 (fr) AMELIORATION DE LA STABILITE DE LA PROTEINE FLINT ( i FAS LIGAND INHIBITORY PROTEIN /i ) PAR GLYCOSYLATION A LIAISON O
CN103370334B (zh) 修饰的人肿瘤坏死因子受体-i多肽或其片段及其制备方法
US20030055221A1 (en) Stability of flint through o-linked glycosylation
KR20220083784A (ko) 혈청 알부민과 성장 호르몬의 융합 단백질의 제조 방법
CA2565227A1 (fr) Derives de la proteine c3 du complement a fonctions de type facteur du venin de cobra
WO2000058466A2 (fr) Analogues de flint resistant aux proteases
CN113396163B (zh) 一种融合蛋白及其制法和用途
WO2001018055A1 (fr) Composes d'analogue de flint et leurs formulations
WO1994029340A1 (fr) Facteur d'inhibition de la proliferation de cellules tumorales d'origine humaine
CA2413754C (fr) Facteur de croissance d'hepatocyte canine
WO2002060947A2 (fr) Glycoformes d'analogue de flint
JP3002104B2 (ja) 顆粒球コロニー刺激因子受容体のリガンド結合領域蛋白質ｂｃをコードしているｄｎａ
JP2839837B2 (ja) 顆粒球コロニー刺激因子受容体のリガンド結合領域蛋白質をコードしているｄｎａ
US7122342B1 (en) Protease-activated receptor PAR4 (ZCHEMR2)
US20040176279A1 (en) Flint glycoforms
JP2007530009A (ja) ポリペプチドを産生する方法
CA2410762A1 (fr) Facteur de croissance d'hepatocyte felin
JPWO1997042319A1 (ja) 新規Ｆａｓ抗原誘導体
JPH05178899A (ja) 修飾ポリペプチドおよびそれを有効成分とする血小板減少症治療剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2000982080

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10129709

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000982080

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000982080

Country of ref document: EP